Publication | Closed Access

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Switchmrk 1Treatment And PreventionHuman RetrovirusClinical TrialsAntiviral TherapyVirologySuppressed ViraemiaPharmacotherapyChronic Viral InfectionAntiviral DrugHivMedicineStable Hiv-infected Patients